Early access program for rintatolimod for the treatment of chronic fatigue syndrome in patients with an unmet medical need

Trial Profile

Early access program for rintatolimod for the treatment of chronic fatigue syndrome in patients with an unmet medical need

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Chronic fatigue syndrome; Pancreatic cancer
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 10 Jul 2017 According to a Hemispherx Biopharma media release, 12 pancreatic patients are undergoing treatment , in the Netherlands it is designed to treat up to 50 pancreatic patients. Top line data from the program is expected to be reported before year-end.
    • 10 Jul 2017 According to a Hemispherx Biopharma media release, the program is being conducted at Erasmus Medical Center in Rotterdam under the supervision of lead clinician C.H.J. (Casper) van Eijck, MD.
    • 11 Jan 2017 According to a Hemispherx Biopharma media release, this Early Access Program has been extended to pancreatic cancer patients beginning in the Netherlands.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top